T1	Participants 45 95	anemic cancer patients on combination chemotherapy
T2	Participants 123 190	advanced cancer frequently experience clinically significant anemia
T3	Participants 823 924	patients with advanced cancer who were receiving myelosuppressive chemotherapy (excluding cisplatin).
